HPLC assay confirms that intracellular accumulation of imatinib is accompanied by upregulation of SLC22A4 through SOS1 inhibition in both sensitive and resistant chronic myeloid leukemia cells. Here, SOS1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.